Acetaminophen Dextromethorphan Hydrobromide Doxyla

證據等級: L5

預測適應症: 0 個

Acetaminophen / Dextromethorphan / Doxylamine / Pseudoephedrine: Cold & Flu Combination — Repurposing Assessment

One-Sentence Summary

This four-component combination (acetaminophen, dextromethorphan HBr, doxylamine succinate, pseudoephedrine) is a classic multi-symptom cold and flu remedy targeting fever, cough, nasal congestion, and sleep disruption. The TxGNN model was unable to generate a repurposing prediction for this combination — no DrugBank ID is available for the combination as a whole, and the predicted_indications array returned empty. Due to the complete absence of prediction output and multiple critical data gaps in this Evidence Pack, this candidate cannot be meaningfully evaluated at this time.

Quick Overview

Item	Content
Original Indication	Multi-symptom cold & flu relief (fever, cough, nasal congestion, sleep disruption)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	N/A — No prediction generated
US Market Status	Not marketed (as this exact 4-component combination)
Number of NDAs	0
Recommended Decision	Hold

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

No NDA records were found for this exact four-component combination in the regulatory database.

Note: Each individual component is widely available in the US as an OTC active ingredient — for example, similar combinations are sold under brand names such as NyQuil Severe. The 0-record result reflects the database query finding no registration under this specific multi-ingredient string. A brand-name or NDA-level search may yield results.

Safety Considerations

Please refer to the package insert for safety information.

This combination contains four pharmacologically active components with distinct and overlapping safety profiles. Key areas warranting review before any repurposing work include:

Doxylamine succinate (sedating antihistamine): CNS depression risk, additive sedation with other CNS-active agents

Pseudoephedrine (sympathomimetic decongestant): cardiovascular stimulant effects, hypertension risk, contraindicated in MAO inhibitor users

Dextromethorphan HBr (NMDA antagonist / σ-1 agonist): serotonin syndrome risk at high doses or with serotonergic drugs

Acetaminophen: hepatotoxicity risk at overdose or in patients with liver impairment or alcohol use

Conclusion and Next Steps

Decision: Hold

Rationale: TxGNN returned no repurposing predictions for this entry, and both DrugBank mapping and safety data are absent — the minimum prerequisites for a repurposing evaluation are not met.

To proceed, the following is needed:

Decompose the combination: Assign individual DrugBank IDs to each of the four components (acetaminophen, dextromethorphan, doxylamine, pseudoephedrine) and re-run TxGNN predictions on each ingredient separately
Identify any brand NDA: Determine whether a specific brand-name product (e.g., NyQuil Severe, Vicks Formula 44, or equivalent) holds an NDA, and re-query the regulatory database by brand name or active ingredient list
Retrieve full prescribing information: Download FDA-approved labeling (package insert PDF) from FDA.gov to populate key warnings, contraindications, and drug interaction data
Clarify analysis scope: Decide whether the research question targets the combination as a unit (e.g., exploring the DXM component for CNS indications) or individual components — this determines the correct TxGNN query strategy
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.